Plain-English translation of NCT07497399 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help slow the brain and nerve damage that happens in multiple sclerosis. The medication works by reducing inflammation and protecting nerve cells. Researchers will compare people who receive the medication to those who receive a placebo (a dummy injection with no active drug) to see if the treatment slows down brain shrinkage.
Multiple sclerosis causes the brain and nerve cells to gradually shrink and die. Current MS treatments focus mainly on preventing relapses, but this medication targets a different problem—it may protect brain tissue from damage even when the disease is stable. This trial is exploring a new way to slow the underlying nerve damage.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either the new medication or a placebo injection once per week. The medication starts at a lower dose for the first 4 weeks, then increases to the full dose. You will have regular brain MRI scans to measure whether the medication is slowing brain shrinkage. The trial involves visits to Johns Hopkins University where researchers will monitor your health and check for any side effects.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States